Statements (65)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:accessories |
gptkb:U._S._government
gptkb:Australia gptkb:Canada gptkb:European_Union gptkb:Japan gptkb:United_Kingdom |
| gptkbp:approves |
gptkb:U._S._Food_and_Drug_Administration
|
| gptkbp:average_temperature |
-20 degrees Celsius
|
| gptkbp:brand |
gptkb:Spikevax
|
| gptkbp:clinical_trial |
30,000
Phase 3 published in NEJM |
| gptkbp:developed_by |
Moderna, Inc.
|
| gptkbp:distribution |
worldwide
|
| gptkbp:dosage_form |
recommended
|
| gptkbp:dose_interval |
28 days
|
| gptkbp:emergency_services |
granted
|
| gptkbp:first_dose |
two doses
|
| https://www.w3.org/2000/01/rdf-schema#label |
Moderna vaccine
|
| gptkbp:is_effective_against |
94.1%
|
| gptkbp:is_vulnerable_to |
gptkb:Operation_Warp_Speed
gptkb:m_RNA-1273 December 18, 2020 ongoing ongoing studies adverse event reporting freezer safety studies lipid nanoparticles reduces transmission long-term studies effectiveness studies reduces infection rates viral vector vaccine against severe disease against hospitalization against symptomatic infection against death reduces mortality rates reduces hospitalization rates through healthcare providers reduces severity of illness through mass vaccination events through pharmacies through vaccination sites |
| gptkbp:manufacturer |
Moderna, Inc.
|
| gptkbp:route_of_administration |
intramuscular injection
|
| gptkbp:side_effect |
fatigue
headache muscle pain fever joint pain |
| gptkbp:targets |
gptkb:COVID-19
|
| gptkbp:type |
gptkb:vaccine
|
| gptkbp:vaccine_dosing_schedule |
2 doses, 28 days apart
|
| gptkbp:vaccine_indication |
prevention of COVID-19
|
| gptkbp:vaccine_public_health |
contributes to herd immunity
part of vaccination campaigns reduces burden on healthcare systems |
| gptkbp:vaccine_shelf_life |
6 months
|
| gptkbp:vaccine_storage_temperature |
-80 to -60 degrees Celsius
|
| gptkbp:bfsParent |
gptkb:B.1.1.7_variant
gptkb:NHS_COVID-19_vaccination_program |
| gptkbp:bfsLayer |
7
|